Canada Markets open in 1 hr 13 mins

Bioasis Technologies Inc. (BTI.V)

TSXV - TSXV Real Time Price. Currency in CAD
Add to watchlist
0.2850-0.0050 (-1.72%)
At close: 3:32PM EDT
Full screen
Previous Close0.2900
Open0.3000
Bid0.2850 x 0
Ask0.3000 x 0
Day's Range0.2850 - 0.3000
52 Week Range0.1400 - 0.4000
Volume9,350
Avg. Volume46,380
Market Cap19.34M
Beta (5Y Monthly)0.56
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
All
News
Press Releases
  • Business Wire

    Bioasis Announces Filing of Its Quarter and Financial Statements and MD&A for the Period Ending May 31, 2020

    BIOASIS TECHNOLOGIES INC. (TSXV:BTI.V; OTCQB:BIOAF), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3™ platform technology for the delivery of therapeutics across the blood-brain barrier ("BBB") and the treatment of central nervous system ("CNS") disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases, today announced it has filed its unaudited quarterly financial statements and management’s discussion and analysis for the period ended May 31, 2020. All are available under the Company’s profile on SEDAR at www.sedar.com and on the Company’s website at www.bioasis.us/investors/.

  • Bioasis and Chiesi Group to Host Webcast on July 16, 2020
    Business Wire

    Bioasis and Chiesi Group to Host Webcast on July 16, 2020

    BIOASIS TECHNOLOGIES INC. ("Bioasis") (TSXV:BTI.V; OTCQB:BIOAF), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3 TM platform technology for the delivery of therapeutics across the blood-brain barrier ("BBB") and the treatment of central nervous system ("CNS") disorders in areas of high unmet medical need, including rare genetic diseases, brain cancers, neurodegenerative diseases and pain, and Chiesi Global Rare Diseases, a business unit of Chiesi Group, an international research-focused healthcare Group, today announced that the companies will host a webcast presentation and conference call at 1:30 p.m. EDT on Thursday, July 16, 2020 to discuss the previously announced Rare Diseases Strategic Alliance.

  • Business Wire

    Bioasis Announces Stock Option Grants

    BIOASIS TECHNOLOGIES INC. (TSXV:BTI.V; OTCQB:BIOAF), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3™ platform technology for the delivery of therapeutics across the blood-brain barrier ("BBB") and the treatment of central nervous system ("CNS") disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases, today announced that it has granted stock options to acquire a total of 1,495,000 common shares effective June 30, 2020 at a price of $0.31 per share to directors and officers of the company. All of the options expire five years from the date of the grant and are governed by the terms of the company’s stock option plan. The options are being issued as part of annual remuneration.